| Application: | 9310, Associations of blood biomarkers with cardiovascular disease and related cardiometabolic outcomes and risk prediction in the clinical setting |
| Title: | Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease |
| Size: | 363327 B |
| Archived: | 23 Nov 2020 |
| Stability: | Complete |
| Personal: | No individual-level data |
Return 2845
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Notes
We were looking for relatively cheap and easy ways to improve our predictions about who is at risk of serious cardiovascular disease in the future, based on their current health. Currently, lipid-associated CVD risk is incorporated into risk scores using total and HDL cholesterol, but there is much controversy around whether apolipoproteins may offer superior prediction. We compared and contrasted these different protein and lipid measures to see which performed best, and found that the traditional lipids (total and HDL cholesterol) were overall the best choice to capture lipid-associated CVD risk and should continue to be used in future, without the added expense of measuring apolipoproteins for this purpose.Application 9310
Associations of blood biomarkers with cardiovascular disease and related cardiometabolic outcomes and risk prediction in the clinical setting
In UK Biobank planned blood tests are important in helping detect early signs of groups of related diseases in the heart, blood vessels, brain, as well as early signs of diabetes. We will investigate to what extent these blood tests tell us about how likely someone is to develop these conditions, how these conditions develop, and whether we can intervene. For instance, adding information from these tests might improve our ability to predict the risk of a person having a heart attack. By harnessing the power of genes, we will test whether some of these new markers cause disease. This project will aim to assess avenues to improve health care throughout the population by investigating the improvement of CVD risk scores. More sensitive CVD and related risk scores may lead to better targeting of treatment and a reduction in the burden of CVD in the population. Biomarker measurement in UK biobank has been commenced, and the first tranche of biomarkers to be measured are now known. We will assess whether these markers are associated with, and predict, risk of cardiovascular and metabolic-related conditions. Biomarkers of interest include: Lipids and lipoproteins (different measures of blood cholesterol), markers of inflammation, markers, of liver function, markers of renal function, sex hormones, markers of glucose control, and markers of bone health. Each of these has plausible biological mechanisms linking them to risk of cardiovascular and metabolic diseases. The full cohort with available data will be explored to maximise generalisability to the whole adult population.
| Lead investigator: | Professor Naveed Sattar |
| Lead institution: | University of Glasgow |
4 related Returns
| Return ID | App ID | Description | Archive Date |
|---|---|---|---|
| 2617 | 9310 | Association of Total and Differential Leukocyte Counts With Cardiovascular Disease and Mortality in the UK Biobank | 28 Oct 2020 |
| 3638 | 9310 | Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease | 9 Jul 2021 |
| 3671 | 9310 | Glycated Hemoglobin, Prediabetes, and the Links to Cardiovascular Disease: Data From UK Biobank | 27 Jul 2021 |
| 2844 | 9310 | Urinary Sodium Excretion, Blood Pressure, and Risk of Future Cardiovascular Disease and Mortality in Subjects Without Prior Cardiovascular Disease | 23 Nov 2020 |
1 Publication
| Pub ID | Title | Author(s) | Year | Journal |
|---|---|---|---|---|
| 2846 | Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease: Data from UK Biobank | Claire Welsh (+15) | 2019 | Circulation |
Enabling scientific discoveries that improve human health